Baker McKenzie client hearX, maker of Lexie hearing aids, has completed its merger with Eargo, forming a new company called LXE Hearing. Backed by an additional USD 100 million investment from Patient Square Capital, the deal is the first notable combination for the over-the-counter hearing aid market since the FDA established the regulatory category in 2022.
Led by M&A/private equity partner Airi Hammalov and tax partner Matt Hayes, the Baker McKenzie team advising hearX included:
- Corporate/M&A – Jon Susko, Gwen Karanadze, Lewis Assness, Matt Bratovich
- Tax – Rob Clary
- Financing – Kevin Whittam, Mark Katz, Nick Brock
- Employment & Benefits – Chris Guldberg, Kimberly Franko, Damiya Park
- Intellectual Property/IT – Adam Aft, Alysha Preston
- Environmental – John Watson
- Anti-Corruption – Geoff Martin, Stephanie Metherall
- Regulatory – Rod Hunter, John Fedele, Heidi Smucker
- Trade – Eunkyung Kim Shin, Lise Test, Alexandra Kumar, William Logsdon
Learn more about the deal: Eargo and hearX Close Merger, Announce New Combined Company, LXE Hearing
With more than 2,700 deal practitioners in 45 jurisdictions, Baker McKenzie is a transactional powerhouse. The Firm's Healthcare & Life Sciences group, one of the largest of any international law firm comprising more than 800 lawyers, has become trusted advisors to the world's largest pharmaceutical, biotech, medical device, medtech, digital health and healthcare services companies. With more than 60 years of experience advising healthcare and life sciences companies, Baker Mckenzie understands the challenges industry players face and what it takes to overcome them.